Gujarat Themis Biosyn Limited Announces Unaudited Financial Results for Q3 FY26
Gujarat Themis Biosyn Limited reported unaudited financial results for Q3 FY26. For the nine months ended Dec 31, 2025, total income was ₹1753.074 lakh and net profit was ₹3.386 lakh. For the quarter ended Dec 31, 2025, total income was ₹566.015 lakh and net loss was ₹64.548 lakh. Board approved results on Feb 5, 2026.
The announcement is a routine disclosure of financial results as per SEBI regulations. The financial performance for the quarter indicates a net loss, and there are no significant positive or negative developments mentioned that would significantly impact the company's stock or operations.
The announcement reports the unaudited financial results for the quarter and nine months ended December 31, 2025. While the company has published its results, the financial performance for the quarter shows a net loss, which tempers a positive sentiment. The overall financial outcome is neutral.
Gujarat Themis Biosyn Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 5, 2026. The detailed financial results, along with the limited review report by statutory auditors GMJ & Co., are available on the company's website (www.gtbl.in) and the websites of the BSE (www.bseindia.com) and NSE (www.nseindia.com). The company has also complied with Regulation 47 of SEBI Listing Regulations by publishing these results in newspapers.
The financial highlights for the nine months ended December 31, 2025, show a total income from operations of ₹1753.074 lakh and a net profit of ₹3.386 lakh. For the quarter ended December 31, 2025, the total income from operations was ₹566.015 lakh, with a net profit of ₹-64.548 lakh. The company's equity share capital stands at ₹1200.000 lakh. The results were reviewed by the Audit Committee and approved by the Board of Directors.
This announcement serves as a notification for the publication of these financial results as required by SEBI regulations.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.